Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 26Dermatologic 3Tumor-Agnostic 1Other hematologic neoplasm 1Endocrine 1Breast 1

Conditions

Uveal Melanoma 3

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × aflibercept × Dermatologic × Clear all
NCT06121180 2025-12-04

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
32 enrolled
Dermatologic

Uveal Melanoma

NCT03712904 2025-09-24

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
3 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT03172299 2025-03-24

PROTECT

Centre Hospitalier Universitaire de Nice

Phase 3 Completed
57 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡